Girard Partners LTD. decreased its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 7.6% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,104 shares of the biopharmaceutical company’s stock after selling 2,459 shares during the period. Girard Partners LTD.’s holdings in Bristol-Myers Squibb were worth $1,919,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after acquiring an additional 15 shares during the period. Jackson Grant Investment Advisers Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.4% during the 2nd quarter. Jackson Grant Investment Advisers Inc. now owns 3,905 shares of the biopharmaceutical company’s stock worth $218,000 after acquiring an additional 15 shares during the period. Chilton Investment Co. LLC grew its holdings in shares of Bristol-Myers Squibb by 0.5% during the 2nd quarter. Chilton Investment Co. LLC now owns 5,283 shares of the biopharmaceutical company’s stock worth $294,000 after acquiring an additional 26 shares during the period. Keel Point LLC grew its holdings in shares of Bristol-Myers Squibb by 0.6% during the 2nd quarter. Keel Point LLC now owns 6,325 shares of the biopharmaceutical company’s stock worth $352,000 after acquiring an additional 39 shares during the period. Finally, Hudock Capital Group LLC grew its stake in shares of Bristol-Myers Squibb by 0.4% in the 2nd quarter. Hudock Capital Group LLC now owns 11,775 shares of the biopharmaceutical company’s stock worth $656,000 after buying an additional 49 shares during the last quarter. 69.74% of the stock is owned by institutional investors and hedge funds.

Several research firms recently weighed in on BMY. Zacks Investment Research upgraded Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price target on the stock. in a research note on Thursday, September 28th. Jefferies Group restated a “buy” rating and issued a $72.00 price target on shares of Bristol-Myers Squibb in a research note on Wednesday, September 27th. Piper Jaffray Companies restated a “hold” rating and issued a $60.00 price target on shares of Bristol-Myers Squibb in a research note on Friday, October 27th. Finally, Citigroup upped their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $65.11.

Shares of Bristol-Myers Squibb Co (BMY) opened at $62.28 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a 52 week low of $46.01 and a 52 week high of $66.10. The company has a market capitalization of $101,933.67, a price-to-earnings ratio of 21.04, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the consensus estimate of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. During the same quarter in the prior year, the business posted $0.77 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. equities research analysts anticipate that Bristol-Myers Squibb Co will post 2.99 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, February 1st. Shareholders of record on Friday, January 5th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.57%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date is Thursday, January 4th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently 62.99%.

In other Bristol-Myers Squibb news, EVP Sandra Leung sold 156,582 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares in the company, valued at approximately $37,031,717.01. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Theodore R. Samuels II bought 4,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were acquired at an average price of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://theolympiareport.com/2018/01/21/bristol-myers-squibb-co-bmy-holdings-reduced-by-girard-partners-ltd.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.